4,954 United Therapeutics Corporation $UTHR Shares Bought by University of Texas Texas AM Investment Management Co.

Posted by Stanley Muller on Nov 9th, 2026

University of Texas Texas AM Investment Management Co. raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 53.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 14,282 shares of the biotechnology company’s stock after buying an additional 4,954 shares during the period. United Therapeutics comprises about 1.0% of University of Texas Texas AM Investment Management Co.’s portfolio, making the stock its 22nd largest holding. University of Texas Texas AM Investment Management Co.’s holdings in United Therapeutics were worth $7,739,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Toth Financial Advisory Corp lifted its holdings in shares of United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 48 shares during the period. Fiduciary Financial Advisors acquired a new stake in United Therapeutics during the second quarter worth about $30,000. Caitlin John LLC acquired a new stake in United Therapeutics during the second quarter worth about $37,000. International Assets Investment Management LLC grew its holdings in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 64 shares during the period. Finally, PFS Partners LLC purchased a new position in United Therapeutics during the third quarter valued at approximately $45,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. BTIG Research upped their price objective on United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Morgan Stanley raised their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $700.00 to $703.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $728.00 target price on shares of United Therapeutics in a report on Wednesday, October 14th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $676.40.

Get Our Latest Analysis on UTHR

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 401,528 shares of company stock valued at $213,440,124. 8.60% of the stock is owned by insiders.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: Analysts raised their price targets and kept bullish ratings. BTIG maintained a Buy rating with a $768 target, citing Tyvaso momentum; Royal Bank of Canada raised its target to $725 and TD Cowen to $700. BTIG analyst outlook
Positive Sentiment: Third-quarter revenue increased 4.1% year over year to $832.5 million, exceeding analyst expectations of about $781 million. The company also has a $2 billion share-repurchase authorization, which could support demand for its shares.
Negative Sentiment: Quarterly EPS of $5.71 missed the $6.01 consensus and was below $7.16 a year earlier. The earnings shortfall and year-over-year decline in EPS could offset the revenue beat.
Negative Sentiment: CEO Martine Rothblatt reported multiple share sales, while EVP Paul Mahon sold 8,300 shares. Insider sales can unsettle investors, although both executives retained substantial holdings after their transactions. CEO sale filing EVP sale filing

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $562.02 on Monday. The firm has a 50-day simple moving average of $533.99 and a two-hundred day simple moving average of $533.42. The company has a market cap of $23.94 billion, a P/E ratio of 21.21, a price-to-earnings-growth ratio of 3.78 and a beta of 0.49. United Therapeutics Corporation has a fifty-two week low of $444.04 and a fifty-two week high of $614.23.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The firm had revenue of $832.50 million for the quarter, compared to analysts’ expectations of $781.14 million. During the same period in the previous year, the company earned $7.16 earnings per share. The company’s revenue was up 4.1% compared to the same quarter last year. Equities research analysts forecast that United Therapeutics Corporation will post 24.77 EPS for the current year.

United Therapeutics announced that its board has approved a share buyback plan on Thursday, October 22nd that allows the company to repurchase $2 billion in shares. This repurchase authorization allows the biotechnology company to repurchase up to 8.3% of its shares through open market purchases. Stock repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

United Therapeutics Profile

(Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.